155 related articles for article (PubMed ID: 26801760)
1. Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells.
Park CH; Cho SY; Ha JD; Jung H; Kim HR; Lee CO; Jang IY; Chae CH; Lee HK; Choi SU
BMC Cancer; 2016 Jan; 16():35. PubMed ID: 26801760
[TBL] [Abstract][Full Text] [Related]
2. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Src impairs the growth of met-addicted gastric tumors.
Bertotti A; Bracco C; Girolami F; Torti D; Gastaldi S; Galimi F; Medico E; Elvin P; Comoglio PM; Trusolino L
Clin Cancer Res; 2010 Aug; 16(15):3933-43. PubMed ID: 20628031
[TBL] [Abstract][Full Text] [Related]
4. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models.
Gavine PR; Ren Y; Han L; Lv J; Fan S; Zhang W; Xu W; Liu YJ; Zhang T; Fu H; Yu Y; Wang H; Xu S; Zhou F; Su X; Yin X; Xie L; Wang L; Qing W; Jiao L; Su W; Wang QM
Mol Oncol; 2015 Jan; 9(1):323-33. PubMed ID: 25248999
[TBL] [Abstract][Full Text] [Related]
5. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification.
Okamoto W; Okamoto I; Arao T; Kuwata K; Hatashita E; Yamaguchi H; Sakai K; Yanagihara K; Nishio K; Nakagawa K
Mol Cancer Ther; 2012 Jul; 11(7):1557-64. PubMed ID: 22729845
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma.
Du Z; Caenepeel S; Shen Y; Rex K; Zhang Y; He Y; Tang ET; Wang O; Zhong W; Zhou H; Huang J; Huang E; Hu L; Coxon A; Zhang M
Mol Cancer Ther; 2016 Jun; 15(6):1227-37. PubMed ID: 27196749
[TBL] [Abstract][Full Text] [Related]
7. SB365, Pulsatilla saponin D, targets c-Met and exerts antiangiogenic and antitumor activities.
Hong SW; Jung KH; Lee HS; Son MK; Yan HH; Kang NS; Lee J; Hong SS
Carcinogenesis; 2013 Sep; 34(9):2156-69. PubMed ID: 23671132
[TBL] [Abstract][Full Text] [Related]
8. M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers.
Ohashi Y; Okamura M; Hirosawa A; Tamaki N; Akatsuka A; Wu KM; Choi HW; Yoshimatsu K; Shiina I; Yamori T; Dan S
Cancer Res; 2016 Jul; 76(13):3895-903. PubMed ID: 27197184
[TBL] [Abstract][Full Text] [Related]
9. KRC-327, a selective novel inhibitor of c-Met receptor tyrosine kinase with anticancer activity.
Park BH; Jung KH; Yun SM; Hong SW; Ryu JW; Jung H; Ha JD; Lee J; Hong SS
Cancer Lett; 2013 May; 331(2):158-66. PubMed ID: 23340177
[TBL] [Abstract][Full Text] [Related]
10. Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer.
Francica P; Nisa L; Aebersold DM; Langer R; Bladt F; Blaukat A; Stroka D; Martínez MR; Zimmer Y; Medová M
Clin Cancer Res; 2016 Nov; 22(21):5322-5336. PubMed ID: 27185371
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo.
Han SY; Lee CO; Ahn SH; Lee MO; Kang SY; Cha HJ; Cho SY; Ha JD; Ryu JW; Jung H; Kim HR; Koh JS; Lee J
Invest New Drugs; 2012 Apr; 30(2):518-23. PubMed ID: 21080208
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
Ji F; Liu X; Wu Y; Fang X; Huang G
Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
[TBL] [Abstract][Full Text] [Related]
13. Ganetespib induces G2/M cell cycle arrest and apoptosis in gastric cancer cells through targeting of receptor tyrosine kinase signaling.
Lee H; Saini N; Parris AB; Zhao M; Yang X
Int J Oncol; 2017 Sep; 51(3):967-974. PubMed ID: 28713919
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of triazolopyridazines substituted with methylisoquinolinone as selective c-Met kinase inhibitors.
Ryu JW; Han SY; Yun JI; Choi SU; Jung H; Ha JD; Cho SY; Lee CO; Kang NS; Koh JS; Kim HR; Lee J
Bioorg Med Chem Lett; 2011 Dec; 21(23):7185-8. PubMed ID: 22001029
[TBL] [Abstract][Full Text] [Related]
15. C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.
Wang L; Yin J; Wang X; Shao M; Duan F; Wu W; Peng P; Jin J; Tang Y; Ruan Y; Sun Y; Gu J
Gastroenterology; 2016 May; 150(5):1183-1195.e16. PubMed ID: 26855187
[TBL] [Abstract][Full Text] [Related]
16. A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors.
Torti D; Sassi F; Galimi F; Gastaldi S; Perera T; Comoglio PM; Trusolino L; Bertotti A
Int J Cancer; 2012 Mar; 130(6):1357-66. PubMed ID: 21500189
[TBL] [Abstract][Full Text] [Related]
17. In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.
Hughes PE; Rex K; Caenepeel S; Yang Y; Zhang Y; Broome MA; Kha HT; Burgess TL; Amore B; Kaplan-Lefko PJ; Moriguchi J; Werner J; Damore MA; Baker D; Choquette DM; Harmange JC; Radinsky R; Kendall R; Dussault I; Coxon A
Mol Cancer Ther; 2016 Jul; 15(7):1568-79. PubMed ID: 27196782
[TBL] [Abstract][Full Text] [Related]
18. Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer.
Lu J; Li G; He K; Jiang W; Xu C; Li Z; Wang H; Wang W; Wang H; Teng X; Teng L
J Transl Med; 2015 Feb; 13():42. PubMed ID: 25638174
[TBL] [Abstract][Full Text] [Related]
19. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.
Bladt F; Faden B; Friese-Hamim M; Knuehl C; Wilm C; Fittschen C; Grädler U; Meyring M; Dorsch D; Jaehrling F; Pehl U; Stieber F; Schadt O; Blaukat A
Clin Cancer Res; 2013 Jun; 19(11):2941-51. PubMed ID: 23553846
[TBL] [Abstract][Full Text] [Related]
20. Heat-shock protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibitors and confers resistance to MET-targeted therapy.
Musiani D; Konda JD; Pavan S; Torchiaro E; Sassi F; Noghero A; Erriquez J; Perera T; Olivero M; Di Renzo MF
FASEB J; 2014 Sep; 28(9):4055-67. PubMed ID: 24903273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]